

January 25, 2018



## Interpace Diagnostics to Present at NobleCon14 on January 29

PARSIPPANY, N.J. , Jan. 25, 2018 (GLOBE NEWSWIRE) -- INTERPACE DIAGNOSTICS GROUP, INC.(NASDAQ:IDXG), a fully integrated commercial and bioinformatics company that provides clinically useful molecular diagnostic tests and pathology services for improved patient diagnosis and management, today announced that its President & CEO, Jack Stover will present at NobleCon14 - Noble Capital Markets' Fourteenth Annual Investor Conference at the W Hotel, Fort Lauderdale, Florida - on Monday, January 29, 2018 at 5:00 pm ET.

A high-definition, video webcast of the presentation will be available the following day on the Company's web site <http://www.interpacediagnostics.com>, and as part of a complete catalog of presentations available at Noble Capital Markets' websites: [www.noblecapitalmarkets.com](http://www.noblecapitalmarkets.com), and [www.nobleconference.com](http://www.nobleconference.com). A Microsoft Silver-Light viewer (a free download from the presentation link) is required to participate. The webcast and presentation will be archived on the company's website and on the Noble websites for 90 days following the event.

### About Interpace Diagnostics

Interpace currently has four commercialized molecular tests and one test in a clinical evaluation process (CEP); PancreGEN® for the diagnosis and prognosis of pancreatic cancer from pancreatic cysts; ThyGenX®, for the diagnosis of thyroid cancer from thyroid nodules utilizing a next generation sequencing assay; ThyraMIR®, for the diagnosis of thyroid cancer from thyroid nodules utilizing a proprietary gene expression assay; and RespriDX™ that differentiates lung cancer of primary vs. metastatic origin. BarreGEN® for Barrett's Esophagus, is currently being "soft launched" with key opinion leaders as we continue to gather data on this assay that will assist us in seeking favorable reimbursement as well as important clinical information. The Company's data base includes data from over 45,000 patients who have been tested using the Company's current products, including over 15,000 molecular tests for thyroid nodules. Interpace has been designated as one of the top 20 companies for providing bioinformatics solutions. Interpace's mission is to provide personalized medicine through molecular diagnostics, innovation and data to advance patient care based on rigorous science. For more information, please visit Interpace's website at [www.interpacediagnostics.com](http://www.interpacediagnostics.com).

### About Noble Capital Markets, Inc.

Noble Capital Markets, established in 1984, is an equity-research driven, full-service, investment & merchant banking boutique focused on the healthcare, media & entertainment, technology, transportation & logistics and natural resources sectors. The company has offices in Boca Raton, New York and Boston and St. Louis. In addition to NobleCon - the annual multi-sector investor conference - and the Media, Finance & Investor Program,

produced in partnership with the National Association of Broadcasters (NAB) and held each spring in Las Vegas, throughout the year Noble hosts numerous “non-deal” corporate road shows across the United States and Canada. Members: FINRA, SIPC, MSRB. [www.noblecapitalmarkets.com](http://www.noblecapitalmarkets.com).

CONTACTS:

Interpace Diagnostics Group, Inc.

Investor Relations:

Paul Kuntz – Redchip

[paul@redchip.com](mailto:paul@redchip.com)



Source: Interpace Diagnostics Group, Inc.